Article
2022 was a year of recovery, discovery, and some losses. While still dealing with the aftermath of COVID-19, rheumatologists were resilient as leaders for their patients and research in advancing rheumatologic care.
All News
Article
Dr. Jack Cush reviews the top abstracts from EULAR 2022 As chosen by me with the aid of the RheumNow EULAR faculty. “Top” is relative and subjective, but my criteria for inclusion are based on impact, water cooler talk potential, innovation and social media buzz. Speaking of social media…
Article
Dr. Jack Frost reviews the news, and journal articles from the past week on RheumNow and ends with an audience question on "Macro-CK".
Article
Hidradenitis suppurativa (HS) (also called acne inversa), is a chronic inflammatory skin disorder affecting apocrine gland-bearing skin in the axillae, groin, and under the breasts and is characterised by
Article
The biosimilar landscape will change dramatically in 2023, following the successful rollouts in other countries in Europe.
Article
ACR22 Convergence left us bountiful with information from all over the world. Here are a few of my personal highlights and key takeaways.
Dr. John Cush
Tweet
For 2023 - what you going to focus on with your patients? Same ole, same ole means youre not getting better. How about focusing on 2 main messages, mine would be patient "STRENGTH" and "COMPLIANCE" (meaning more Rx education) https://t.co/fEIVYk6Z9m
Dr. John Cush
Tweet
Join us for RheumNow Live this March 18-19 in Dallas, TX! We're not like other meetings--we're answering the questions you want answered.
RNL is a meeting to engage your mind and change your practice. Join us in-person or virtually!
https://t.co/bMphD12Bie https://t.co/Hx0uHAIUWd
Dr. John Cush
Tweet
There is considerable overlap between fibromyalgia tender points and an enthesitis score in axial spondyloarthritis pts. 526 pts in the Predict-SpA study (53% men, 38% FM) assessed 18 TP and 13 Entheses found ICC between both scores of 0.7 https://t.co/ESmP26plDB https://t.co/7X1XhyML0f
Dr. John Cush
Tweet
Many have quoted and shown this image of Ankylosing Spondylitis in a young military recruit at age 25, 35, 45, 50 & 51yrs. This may be the MOST used slide in rheum! It comes from the work of Toronto's Dr. Hugh Little, who sadly passed away at age 58 yrs. https… https://t.co/G28YlyhX3v
Dr. John Cush
Tweet
anti-IL-23 therapy is not effective in Axial Spondyloarthritis. While ustekinumab, guselkumab and risankizumab are approved in psoriasis (& PsA for GUS, RIZ), studies of Ustekinumab and risankizumab failed to show efficacy in axSpA https://t.co/hjXEopji6r https://t.co/FwzBa2YNzb
Dr. John Cush
Tweet
Spanish SpA Registry (REGISPONSER) - 18.3% had psoriasis; w/ 3/4 of these (76%) having PSO before MSK Sxs. Pts w/ PSO before MSK Sxs had shorter dz duration, lower BMI, Less B27 & anterior uveitis, more dactylitis and ^risk PsA dx (78% vs 56%)
https://t.co/Kc1n4RVe3v
Dr. John Cush
Tweet
The First Head to Head trial in Axial SpA
Dr.Gensler discusses abstract L15 presented at #ACR22. L15: Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic AxSpA: A Randomized Phase IIIb Study
https://t.co/J0DT1yw0vQ https://t.co/kKhFQKAy6H
Dr. John Cush
Tweet
Comorbidities in Axial Spondyloarthritis
Dr. Antoni Chan discusses Abstract 1609 at ACR22 Convergence.
https://t.co/dCLlgiGV9K https://t.co/a4iI1q3zZC
Dr. John Cush
Tweet
Practical Guidance for the Clinical Rheumatologist in Unplanned Pregnancies
Women of reproductive age comprise an overwhelming majority of patients with rheumatic and musculoskeletal disease.
https://t.co/45ABQ0e2Qy https://t.co/dhLqzjf9uL
Dr. John Cush
Tweet
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler ( @lianegensler discusses the following abstracts presented at #ACR22. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
https://t.co/f7o8UARKNl https://t.co/ryVmD86UoI
Dr. John Cush
Tweet
A Multidimensional Approach in the Management of Axial Spondylarthritis
Abstract 1510 by Jones et al studied the effect of lifestyle on treatment response in patients with axial spondylarthritis.
https://t.co/Y5syU5cX6Y https://t.co/PO7TZ3ZBOo
Dr. John Cush
Tweet
Lifestyle Modifications may enhance TNF Inhibitors in axSpA
https://t.co/0O4jd3g0WL https://t.co/zUaRUR9tGL
Dr. John Cush
Tweet
Follow us on LinkedIn too!
https://t.co/iylzzYRVAB https://t.co/7rKQShIzs5
Dr. John Cush
Tweet
Spondyloarthritis Topic Panel - #ACR22
SpA Panelists: Drs. Lianne Gensler, Antoni Chan, Akhil Sood, Eric Dein, Sheila Reyes, Catherine Sims
@synovialjoints @AkhilSoodMD @ericdeinmd @RHEUMarampa @DrCassySims
https://t.co/uFPW3NxZEm https://t.co/stjmhcFoaS
